Despite few manageable side effects, the favorable outcomes on tumor response and quality of life of trametinib-based therapy in Lebanese pediatric LGG patients suggest that MEK inhibitors may be a feasible option in selected LMIC settings, when appropriate diagnostic and monitoring infrastructure is available.
BACKGROUND
MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities.
METHODS
We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs rec...
Céline Khouri, Amandine Bibollet, Y. Bouchoucha et al.· European Journal of Cancer· 0 citations
Vemurafenib showed efficacy in children with recurrent or progressive BRAFV600E-mutant brain tumors with acceptable toxicity, however, the rebound rate of 23% warrants further investigation.
T. Nicolaides, R. Hoogendijk, Marie Jaeger-Krause et al.· JCO Precision Oncology· 0 citations
Background and aim This retrospective cohort study aimed to characterize the real-world clinical outcomes and treatment-emergent adverse events (TEAEs) of anlotinib-containing regimens among pediatric patients with solid tumors treated at the Children’s Hospital of Zhejiang University School of Medicine from January 20...
Qiao Hua, Zhou Xia, Ya-Qing Gu et al.· Frontiers in Oncology· 0 citations
PURPOSE
Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors.
PATIENTS AND METHODS
In this open-lab...
H. Okuma, A. Arakawa, Akihiro Hirakawa et al.· Clinical Cancer Research· 0 citations
Clinical trials evaluating immune checkpoint inhibitors (ICIs) in unselected childhood cancers have shown low response rates, excluding Hodgkin lymphoma. We sought to describe the real-world antitumor activity and toxicity of ICIs in children, adolescents, and young adults (CAYAs) with solid tumors selected based...
Andy Huy-Dat Vu, M. Brizini, M. Brisson et al.· Cancer Research· 0 citations
PURPOSE
Selpercatinib, a highly selective oral RET inhibitor with CNS activity, has previously demonstrated durable responses and an acceptable safety profile in adults with RET-driven cancers. Consequently, the safety and efficacy of selpercatinib were investigated in pediatric/adolescent participants.
METHODS
LIBRE...
T. Laetsch, H. Kang, M. Casanova et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
